Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):959–964. doi: 10.1038/sj.bjc.6690153

Androgen receptor expression in male breast carcinoma: lack of clinicopathological association

A Pich 1, E Margaria 2, L Chiusa 1, G Candelaresi 2, O Dal Canton 3
PMCID: PMC2362653  PMID: 10070897

Abstract

Androgen receptor (AR) expression was retrospectively analysed in 47 primary male breast carcinomas (MBCs) using a monoclonal antibody on formalin-fixed, paraffin-embedded tissues. AR immunopositivity was detected in 16 out of 47 (34%) cases. No association was found with patient age, tumour stage, progesterone receptor (PGR) or p53 protein expression. Well-differentiated MBCs tended to be AR positive more often than poorly differentiated ones (P= 0.08). A negative association was found between ARs and cell proliferative activity: MIB-1 scores were higher (25.4%) in AR-negative than in AR-positive cases (21.11%; P= 0.04). A strong positive association (P= 0.0001) was found between ARs and oestrogen receptors (ERs). In univariate analysis, ARs (as well as ERs and PGRs) were not correlated with overall survival; tumour histological grade (P= 0.02), size (P= 0.01), p53 expression (P= 0.0008) and MIB-1 scores (P= 0.0003) had strong prognostic value. In multivariate survival analysis, only p53 expression (P= 0.002) and histological grade (P= 0.02) retained independent prognostic significance. In conclusion, the lack of association between AR and most clinicopathological features and survival, together with the absence of prognostic value for ER/PGR status, suggest that MBCs are biologically different from female breast carcinomas and make it questionable to use antihormonal therapy for patients with MBC. © 1999 Cancer Research Campaign

Keywords: androgen receptors, male breast carcinoma, immunohistochemistry, prognosis

Full Text

The Full Text of this article is available as a PDF (200.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alanko A., Heinonen E., Scheinin T., Tolppanen E. M., Vihko R. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer. 1985 Oct 1;56(7):1696–1700. doi: 10.1002/1097-0142(19851001)56:7<1696::aid-cncr2820560738>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  2. Allegra J. C., Lippman M. E., Thompson E. B., Simon R., Barlock A., Green L., Huff K. K., Do H. M., Aitken S. C. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 1979 May;39(5):1447–1454. [PubMed] [Google Scholar]
  3. Anelli T. F., Anelli A., Tran K. N., Lebwohl D. E., Borgen P. I. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer. 1994 Jul 1;74(1):74–77. doi: 10.1002/1097-0142(19940701)74:1<74::aid-cncr2820740113>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  4. Bertuzzi A., Daidone M. G., Di Fronzo G., Silvestrini R. Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer. Breast Cancer Res Treat. 1981;1(3):253–262. doi: 10.1007/BF01806265. [DOI] [PubMed] [Google Scholar]
  5. Bezwoda W. R., Hesdorffer C., Dansey R., de Moor N., Derman D. P., Browde S., Lange M. Breast cancer in men. Clinical features, hormone receptor status, and response to therapy. Cancer. 1987 Sep 15;60(6):1337–1340. doi: 10.1002/1097-0142(19870915)60:6<1337::aid-cncr2820600629>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  6. Birrell S. N., Roder D. M., Horsfall D. J., Bentel J. M., Tilley W. D. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol. 1995 Jul;13(7):1572–1577. doi: 10.1200/JCO.1995.13.7.1572. [DOI] [PubMed] [Google Scholar]
  7. Bruce D. M., Heys S. D., Payne S., Miller I. D., Eremin O. Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol. 1996 Feb;22(1):42–46. doi: 10.1016/s0748-7983(96)91418-3. [DOI] [PubMed] [Google Scholar]
  8. Bryan R. M., Mercer R. J., Bennett R. C., Rennie G. C., Lie T. H., Morgan F. J. Androgen receptors in breast cancer. Cancer. 1984 Dec 1;54(11):2436–2440. doi: 10.1002/1097-0142(19841201)54:11<2436::aid-cncr2820541121>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  9. Calandra R. S., Charreau E. H., Royer de Giaroli M., Baldi A. Incidence of estrogen, progesterone and prolactin receptors in human breast cancer. Prog Clin Biol Res. 1984;142:97–108. [PubMed] [Google Scholar]
  10. Cutuli B., Lacroze M., Dilhuydy J. M., Velten M., De Lafontan B., Marchal C., Resbeut M., Graic Y., Campana F., Moncho-Bernier V. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995 Nov;31A(12):1960–1964. doi: 10.1016/0959-8049(95)00366-5. [DOI] [PubMed] [Google Scholar]
  11. Dawson P. J., Paine T. M., Wolman S. R. Immunocytochemical characterization of male breast cancer. Mod Pathol. 1992 Nov;5(6):621–625. [PubMed] [Google Scholar]
  12. Elston C. W., Ellis I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403–410. doi: 10.1111/j.1365-2559.1991.tb00229.x. [DOI] [PubMed] [Google Scholar]
  13. Everson R. B., Lippman M. E., Thompson E. B., McGuire W. L., Wittliff J. L., De Sombre E. R., Jensen E. V., Singhakowinta A., Brooks S. C., Jr, Neifeld J. P. Clinical correlations of steroid receptors and male breast cancer. Cancer Res. 1980 Apr;40(4):991–997. [PubMed] [Google Scholar]
  14. Fox S. B., Rogers S., Day C. A., Underwood J. C. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol. 1992 Jan;166(1):13–18. doi: 10.1002/path.1711660104. [DOI] [PubMed] [Google Scholar]
  15. Friedman M. A., Hoffman P. G., Jr, Dandolos E. M., Lagios M. D., Johnston W. H., Siiteri P. K. Estrogen receptors in male breast cancer: clinical and pathologic correlations. Cancer. 1981 Jan 1;47(1):134–137. doi: 10.1002/1097-0142(19810101)47:1<134::aid-cncr2820470122>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  16. Gerdes J., Pickartz H., Brotherton J., Hammerstein J., Weitzel H., Stein H. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol. 1987 Dec;129(3):486–492. [PMC free article] [PubMed] [Google Scholar]
  17. Guinee V. F., Olsson H., Moller T., Shallenberger R. C., van den Blink J. W., Peter Z., Durand M., Dische S., Cleton F. J., Zewuster R. The prognosis of breast cancer in males. A report of 335 cases. Cancer. 1993 Jan 1;71(1):154–161. doi: 10.1002/1097-0142(19930101)71:1<154::aid-cncr2820710125>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  18. Hiort O., Kwan P. W., DeLellis R. A. Immunohistochemistry of estrogen receptor protein in paraffin sections. Effects of enzymatic pretreatment and cobalt chloride intensification. Am J Clin Pathol. 1988 Nov;90(5):559–563. doi: 10.1093/ajcp/90.5.559. [DOI] [PubMed] [Google Scholar]
  19. Isola J. J. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol. 1993 May;170(1):31–35. doi: 10.1002/path.1711700106. [DOI] [PubMed] [Google Scholar]
  20. Jacobs T. W., Prioleau J. E., Stillman I. E., Schnitt S. J. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst. 1996 Aug 7;88(15):1054–1059. doi: 10.1093/jnci/88.15.1054. [DOI] [PubMed] [Google Scholar]
  21. Joshi M. G., Lee A. K., Loda M., Camus M. G., Pedersen C., Heatley G. J., Hughes K. S. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996 Feb 1;77(3):490–498. doi: 10.1002/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  22. Kuenen-Boumeester V., Van der Kwast T. H., Claassen C. C., Look M. P., Liem G. S., Klijn J. G., Henzen-Logmans S. C. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996 Aug;32A(9):1560–1565. doi: 10.1016/0959-8049(96)00112-8. [DOI] [PubMed] [Google Scholar]
  23. Langer M., Kubista E., Schemper M., Spona J. Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obstet. 1990;247(4):203–209. doi: 10.1007/BF02389545. [DOI] [PubMed] [Google Scholar]
  24. Lea O. A., Kvinnsland S., Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res. 1989 Dec 15;49(24 Pt 1):7162–7167. [PubMed] [Google Scholar]
  25. McGuire W. L., Clark G. M. Role of progesterone receptors in breast cancer. Semin Oncol. 1985 Mar;12(1 Suppl 1):12–16. [PubMed] [Google Scholar]
  26. Mercer R. J., Bryan R. M., Bennett R. C. Hormone receptors in male breast cancer. Aust N Z J Surg. 1984 Jun;54(3):215–218. doi: 10.1111/j.1445-2197.1984.tb05305.x. [DOI] [PubMed] [Google Scholar]
  27. Miller W. R., Telford J., Dixon J. M., Hawkins R. A. Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer Clin Oncol. 1985 Apr;21(4):539–542. doi: 10.1016/0277-5379(85)90049-5. [DOI] [PubMed] [Google Scholar]
  28. Millis R. R. Correlation of hormone receptors with pathological features in human breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2869–2871. doi: 10.1002/1097-0142(19801215)46:12+<2869::aid-cncr2820461426>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  29. Nomura Y., Yamagata J., Takenaka K., Tashiro H. Steroid hormone receptors and clinical usefulness in human breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2880–2883. doi: 10.1002/1097-0142(19801215)46:12+<2880::aid-cncr2820461428>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  30. Pacheco M. M., Oshima C. F., Lopes M. P., Widman A., Franco E. L., Brentani M. M. Steroid hormone receptors in male breast diseases. Anticancer Res. 1986 Sep-Oct;6(5):1013–1017. [PubMed] [Google Scholar]
  31. Pertschuk L. P., Feldman J. G., Kim Y. D., Braithwaite L., Schneider F., Braverman A. S., Axiotis C. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer. 1996 Jun 15;77(12):2514–2519. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2514::AID-CNCR14>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  32. Pertschuk L. P., Kim D. S., Nayer K., Feldman J. G., Eisenberg K. B., Carter A. C., Rong Z. T., Thelmo W. L., Fleisher J., Greene G. L. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer. 1990 Oct 15;66(8):1663–1670. doi: 10.1002/1097-0142(19901015)66:8<1663::aid-cncr2820660802>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  33. Pich A., Margaria E., Chiusa L., Ponti R., Geuna M. DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Hum Pathol. 1996 Jul;27(7):676–682. doi: 10.1016/s0046-8177(96)90397-4. [DOI] [PubMed] [Google Scholar]
  34. Pich A., Margaria E., Chiusa L. Proliferative activity is a significant prognostic factor in male breast carcinoma. Am J Pathol. 1994 Aug;145(2):481–489. [PMC free article] [PubMed] [Google Scholar]
  35. Poulin R., Baker D., Labrie F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat. 1988 Oct;12(2):213–225. doi: 10.1007/BF01805942. [DOI] [PubMed] [Google Scholar]
  36. Prioleau J., Schnitt S. J. p53 antigen loss in stored paraffin slides. N Engl J Med. 1995 Jun 1;332(22):1521–1522. doi: 10.1056/NEJM199506013322217. [DOI] [PubMed] [Google Scholar]
  37. Ribeiro G. Male breast carcinoma--a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer. 1985 Jan;51(1):115–119. doi: 10.1038/bjc.1985.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ribeiro G., Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer. 1992 Feb;65(2):252–254. doi: 10.1038/bjc.1992.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Rogers S., Day C. A., Fox S. B. Expression of cathepsin D and estrogen receptor in male breast carcinoma. Hum Pathol. 1993 Feb;24(2):148–151. doi: 10.1016/0046-8177(93)90293-p. [DOI] [PubMed] [Google Scholar]
  40. Salvadori B., Saccozzi R., Manzari A., Andreola S., Conti R. A., Cusumano F., Grassi M. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer. 1994;30A(7):930–935. doi: 10.1016/0959-8049(94)90117-1. [DOI] [PubMed] [Google Scholar]
  41. Sasano H., Kimura M., Shizawa S., Kimura N., Nagura H. Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab. 1996 Aug;81(8):3063–3067. doi: 10.1210/jcem.81.8.8768875. [DOI] [PubMed] [Google Scholar]
  42. Søreide J. A., Lea O. A., Varhaug J. E., Skarstein A., Kvinnsland S. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992 Apr;18(2):112–118. [PubMed] [Google Scholar]
  43. Teller M. N., Stock C. C., Stohr G., Merker P. C., Kaufman R. J., Escher G. C., Bowie M. Biologic characteristics and chemotherapy of 7,12-dimethylbenz[a]anthracene-induced tumors in rats. Cancer Res. 1966 Feb;26(2):245–252. [PubMed] [Google Scholar]
  44. Walker K. J., Bouzubar N., Robertson J., Ellis I. O., Elston C. W., Blamey R. W., Wilson D. W., Griffiths K., Nicholson R. I. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res. 1988 Nov 15;48(22):6517–6522. [PubMed] [Google Scholar]
  45. Weber-Chappuis K., Bieri-Burger S., Hurlimann J. Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer. 1996 Sep;32A(10):1686–1692. doi: 10.1016/0959-8049(96)00154-2. [DOI] [PubMed] [Google Scholar]
  46. Wilbur D. C., Willis J., Mooney R. A., Fallon M. A., Moynes R., di Sant'Agnese P. A. Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextran-coated charcoal assay. Mod Pathol. 1992 Jan;5(1):79–84. [PubMed] [Google Scholar]
  47. Williams W. L., Jr, Powers M., Wagman L. D. Cancer of the male breast: a review. J Natl Med Assoc. 1996 Jul;88(7):439–443. [PMC free article] [PubMed] [Google Scholar]
  48. Willsher P. C., Leach I. H., Ellis I. O., Bell J. A., Elston C. W., Bourke J. B., Blamey R. W., Robertson J. F. Male breast cancer: pathological and immunohistochemical features. Anticancer Res. 1997 May-Jun;17(3C):2335–2338. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES